Fierce Biotech Homepage

Mike Doustdar
Pharma

Novo CEO talks embracing change and staying bullish amid rebrand

CEO Mike Doustdar told Fierce that there was a recognition, both internally and externally, that Novo needed to make some changes to its business.
Fraiser Kansteiner Sep 17, 2026 8:45am
Daniel ODay
Favicon Fierce Biotech

CEO O’Day tells Fierce how Gilead reached ‘critical mass’

Sep 16, 2026 8:00am
Novo Nordisk
Favicon Fierce Biotech

Novo explores macrocycle potential in $1.4B Danish biotech pact

Sep 17, 2026 7:00am
psychedelic brain think thought hallucinogenic psychology
Favicon Fierce Biotech

FDA holds psychedelic hearing as historic approval looms

Sep 14, 2026 6:00pm
Doustdar

No more Nordisk as Novo goes it alone amid rebranding push

Sep 14, 2026 6:54am
FDA

New FDA oncology chief sets priorities in first interview

Sep 11, 2026 4:00am
More News

Novartis investor calls for board overhaul after costly setbacks

Sep 10, 2026 10:26am

FDA solidifies leadership posts at CDER, CBER

Sep 9, 2026 9:00am

FDA's surprise approval of AZ's oral SERD sets new paradigm

Sep 8, 2026 10:35am

Ionis scores ‘breakthrough’ rare disease approval

Sep 4, 2026 11:18am